Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

R116301

Known as: R 116301 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
PurposeNK1 receptors have been implicated in various neuropsychiatric and other disorders. R116301 is a selective NK1 receptor… Expand
  • figure 1
  • table 1
2009
2009
Purpose: NK1 receptors have been implicated in various neuropsychiatric and other disorders. R116301 is a selective NK1 receptor… Expand
  • figure 1
  • table 1
2006
2006
Research on mechanisms of drug action, and preclinical screening of molecules with a potential activity on neuropathic pain… Expand
2005
2005
Activation of vanilloid receptors has commonly been used to facilitate neurogenic inflammation and plasma exudation to model… Expand
2004
2004
Mu-, kappa- and delta-opioid receptor agonists are reported to attenuate the acetic-acid-induced abdominal constriction response… Expand
2003
2003
Substance P (SP) acts as a transmitter of nociception in both the peripheral and the central nervous system. Because the NK-1… Expand
2002
2002
In comparison with a series of reference compounds, (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4… Expand
2001
2001
The recent development of selective NK(1) receptor antagonists that are active in vivo provides an important research tool to… Expand
1999
1999
To test the effect of the neurokinin‐1 receptor antagonist hydroxybutanedioate (R116301) in human hand veins in vivo.